Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gynecologic 1

Conditions

Ovarian Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Neuroectodermal Tumors 1 Nervous System Diseases 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Esophageal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Specimen Handling 9 Paclitaxel 7 Magnetic Resonance Spectroscopy 6 Carboplatin 6 Biopsy 6 Nivolumab 5 pembrolizumab 3 olaparib 3 X-Rays 3 durvalumab 2 ceralasertib 2 cediranib 2 Taxes 2 Immunoglobulin G 2 trastuzumab deruxtecan 1 sargramostim 1 rucaparib 1 ribociclib 1 rebastinib 1 pelcitoclax 1 pazopanib 1 pamiparib 1 liposomal doxorubicin 1 cobimetinib 1 capivasertib 1 cabozantinib 1 belinostat 1 atezolizumab 1 apatinib 1 Trabectedin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinosarcoma × pamiparib × Sarcoma × Clear all

NCT03933761 2021-08-10

PRECISE

Australia New Zealand Gynaecological Oncology Group

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡